<DOC>
	<DOCNO>NCT01196078</DOCNO>
	<brief_summary>This study compare efficacy safety Tarceva ( erlotinib ) vinorelbine chemo-naive elderly patient advance non-small cell lung cancer . Patients randomize receive either Tarceva ( 150 mg po daily ) vinorelbine ( 60 mg/m2 day 1 8 cycle 1 80 mg/m2 21 day cycle ) . The anticipated time study treatment disease progression .</brief_summary>
	<brief_title>A Study Tarceva ( Erlotinib ) Elderly Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Adult patient , &gt; =70 year age Nonsmall cell lung cancer Naive prior chemotherapy specific immunotherapy Presence least 1 measurable lesion Active noncontrolled infection disease CNS metastases Any malignancy ( adequately treat basal cell cancer skin , situ cancer cervix )</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>